Gilead’s Descovy gains PrEP indication

The FDA approves Gilead’s (GILD +0.2%) Descovy for a pre-exposure prophylaxis indication.

Descovy for PrEP is indicated to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are HIV-negative and at-risk for sexually acquired HIV, excluding those at-risk from receptive vaginal sex.

https://seekingalpha.com/news/3503833-gileads-descovy-gains-prep-indication